HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 1, 2003, Pages

  Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

HIV 1; Nevirapine; NNRTI; Resistance

Indexed keywords

DELAVIRDINE; EFAVIRENZ; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; CONFERENCE PAPER; CROSS RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0141793150     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309011-00002     Document Type: Conference Paper

References (60)

1. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-8337.
2. St Clair MH, Richards CA, Spector T, et al. 3′-Azido-3′ -deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987;31:1972-1977.
3. Yarchoan R, Mitsuya H, Broder S. Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection. Am J Med 1989;87:191-200.
4. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′-deoxy-3′ -thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992;36:1688-1694.
5. Wu JC, Warren TC, Adams J, et al. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 1991;30:2022-2026.
6. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-1790.
7. Ding J, Das K, Moereels H, et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 1995;2:407-415.
8. Spence RA, Kati WM, Anderson KS, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995;267:988-993.
9. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 1995;92:8046-8049.
10. Gu Z, Gao Q, Faust EA, et al. Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J Gen Virol 1995;76 (Pt 10):2601-2605.
11. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
12. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-4892.
13. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1606.
14. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-1579.
15. Gu Z, Gao Q, Li X, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992;66:7128-7135.
16. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′ -dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994;38:275-281.
17. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994;47:155-169.
18. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxy-nucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-2402.
19. Ding J, Das K, Hsiou Y, et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J Mol Biol 1998;284:1095-111.
20. Ren J, Esnouf R, Garman E, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 1995;2:293-302.
21. Arts EJ, Wainberg MA. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996;40:527-540.
22. Loya S, Bakhanashvili M, Tal R, et al. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-and tyrosine 188-leucine), resistant to nonnucleoside inhibitors. AIDS Res Hum Retroviruses 1994;10:939-946.
23. Tantillo C, Ding J, Jacobo-Molina A, et al. Location of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J Mol Biol 1994;243:369-387.
24. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997;71:8893-8898.
25. Hizi A, Tal R, Shaharabany M, et al. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother 1993;37:1037-1042.
26. Shila CK, Rose JM, Hansen GL, et al. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 1991;88:9878-9882.
27. Yang G, Song Q, Charles M, et al. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. J AIDS 1996;11:326-333.
28. Brown AJ, Precious HM, Whitcomb JM, et al. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000;74:10269-10273.
29. Bacheler L, Ploughman L, Hertogs K, et al. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (study DMP 266-006). Antivir Ther 2000;5(suppl 3):70.
30. Harrigan PR, Verbiest W, Larder B, et al. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy [abstract 86]. Antivir Ther 2000;5(suppl 3):68-69.
31. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475-2484.
32. Esnouf R, Ren J, Ross C, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non- nucleoside inhibitors. Nat Struct Biol 1995;2:303-308.
33. Casado JL, Hertogs K, Ruiz L, et al. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000;14:F1-F7.
34. Emini, EA, Graham DJ, Gotlib L, et al. HIV and multidrug resistance. Nature 1993;364:679.
35. Huang W, Gamarnik A, Wrin T, et al. NNRTI-resistance profiles, replicative capacity and protease processing defects in HIV-1 that contain RT mutations at amino acid 190 [abstract 29]. Antivir Ther 2000;5(suppl 3):23.
36. Byrnes VW, Sardana VV, Schleif WA, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother 1993;37:1576-1579.
37. Balzarini J, Pelemans H, Esnouf R, et al. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res Hum Retroviruses 1998;14:255-260.
38. Fujiwara T, Sato A, el-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998;42:1340-1345.
39. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44:2475-2484.
40. Byrnes VW, Emini EA, Schleif WA, et al. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother 1994; 38:1404-1407.
41. Winslow DL, Garber S, Reid C, et al. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 1996;10:1205-1209.
42. Calvez, V, Delaugerre C, Rohban R, et al. Resistance profile and cross-resistance of HIV-1 among 102 patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen [abstract 122]. Antivir Ther 2000;5(suppl 3):97.
43. Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. JAIDS 2000;23:221-226.
44. Byrnes VW, Sardana VV, Schleif WA, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother 1993;37:1576-1579.
45. Deeks SG. Nonnucleoside reverse transcriptase inhibitor resistance. J AIDS 2001;26(suppl 1):S25-S33.
46. Dueweke TJ, Pushkarskaya T, Poppe SM, et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993;90:4713-4717.
47. Demeter LM, Shafer RW, Meehan PM, et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother 2000;44:794-797.
48. Huang W, Parkin NT, Lie YS, et al. A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication [abstract 30]. Antivir Ther 2000;5(suppl 3):24-25.
49. Gerondelis P, Archer RH, Palaniappan C, et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J Virol 1999;73:5803-5813.
50. Byrnes VW, Sardana VV, Schleif WA, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother 1993;37:1576-1579.
51. Pelemans H, Aertsen A, Van Laethem K, et al. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology 2001;280:97-106.
52. Kemp SD, Salim M, Stammers D, et al. A mutation in HIV-1 reverse transcriptase at codon 318 (Y-F) confers high-level non-nucleoside reverse transcriptase inhibitor resistance in clinical samples. Antivir Ther 2001;6(suppl 1):44.
53. Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994;75:951-957.
54. Havlir DV, Eastman S, Gamst A, et al. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70:7894-7899.
55. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992;36:2664-2669.
56. Shulman N, Zolopa AR, Passaro D, et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001;15:1125-1132.
57. Balzarini J. Non-nucleoside reverse transcriptase inhibitors of HIV-1. In Emini, EA (ed.) The Human Immunodeficiency Virus: Biology, Immunology, and Therapy. Princeton, NJ, U.S.A.: Princeton University Press, 2002;132-171.
58. Gu Z, Quan Y, Li Z, et al: Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. J Biol Chem 1995;270:31046-31051.
59. Götte M, Arion D, Parniak MA, et al. The M184V mutation in the reverse transcriptase of the human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000;74:3579-3585.
60. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17:F1-F5.